In this Q&A, Ping Moore, OD, covers emerging dry eye therapies, from selenium sulfide to next-gen cyclosporine, and how subtype-guided care shapes treatment choices.
News|Articles|June 11, 2026
Eyes on May 2026: A month of durable therapies, a regulatory reversal, and rethought mechanisms
Author(s)Ophthalmology Times Staff Reports
Fact checked by: Martin David Harp
Three-year gene therapy data, an FDA reversal in wet AMD, light-powered dry eye treatment, a new macular supplement, and progress in childhood glaucoma—our review breaks down the 5 May 2026 stories that matter.
Advertisement
Advertisement
May 2026 was a busy stretch for clinical and translational eye care. The month brought multi-year durability data for 2 very different approaches to inherited retinal disease (IRD), a regulatory turnaround that could reshape the wet age-related macular degeneration (AMD) market, a genuinely novel mechanism for treating the ocular surface, and a new entry in the long-running conversation about macular nutrition. Here is what stood out.
Related to this article
Two investigational pipeline therapies take aim at the root causes of dry eye disease
Dry eye care pivots to root-cause diagnosis and personalized biologics/devices,
Findings from the third annual State of Dry Eye survey link symptom management to quality of life gains, including lower anxiety and improved self-confidence.
Dry eye cases rise with heavy screen use and younger patients; learn modern workups spotlighting MGD, etiology-driven treatments, and collaborative care reshaping outcomes.
A successful Type B Rare Disease Evidence Principles meeting confirms the pivotal study design, opening a potential BLA pathway on 6-month efficacy data, with dosing expected to begin in the fourth quarter of 2026.
Patients with polyendocrine metabolic ovarian syndrome have higher ocular disease prevalence.
Offline smartphone AI fundus screening detects diabetic retinopathy, glaucoma, and macular degeneration in one capture, delivering high accuracy for low-resource eye care.
Advertisement
Advertisement